Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers

Pharmacology Biochemistry and Behavior

Volumn 66, Issue 3, 2000, Pages 637-643

  Lundahl, Leslie H ^a   Henningfield, Jack E ^b   Lukas, Scott E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PINNEY ASSOCIATES   (United States)

Author keywords

Craving; Human subjects; Mecamylamine; Nicotine; Tobacco

Indexed keywords

MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEART RATE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; REINFORCEMENT; SMOKING CESSATION; VOLUNTEER; WITHDRAWAL SYNDROME;

ADULT; EUPHORIA; HUMANS; MALE; MECAMYLAMINE; NICOTINE; NICOTINIC ANTAGONISTS; SELF ADMINISTRATION; SMOKING; TIME FACTORS;

NICOTIANA TABACUM;

EID: 0033921876     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00252-5     Document Type: Article

References (25)

1. Benowitz N.L., Jacobs P. III. Nicotine and carbon monoxide intake from high- and low-yield cigarettes. Clin. Pharmacol. Ther. 36:1984;265-270.
2. Dworkin S.I., Mirkis S., Smith J.E. Response-dependent versus response-independent presentation of cocaine. Differences in the lethal effects of the drug Psychopharmacology (Berlin). 117:1995;262-266.
3. Gourlay S.G., Benowitz N.L. Arteriovenous differences in plasma concentrations of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin. Pharmacol. Ther. 62:1997;453-463.
4. Griffiths R.R., Bigelow G.E., Henningfield J.E. Similarities in animal and human drug-taking behavior. Mello N.K. Advances in substance abuse, vol. 1. 1980;JAI Press, Inc, Greenwich, CT.
5. Henningfield J.E., Miyasato K., Jasinski D.R. Cigarette smokers self-administer intravenous nicotine. Pharmacol. Biochem. Behav. 19:1983;887-890.
6. Henningfield J.E., Miyasato K., Johnson R.E., Jasinski D.R. Rapid physiologic effects of nicotine in humans and selective blockade of behavioral effects by mecamylamine. Harris L.S. Problems of drug dependence, 1982. NIDA research monogr. No. 43. 1983;259-265 Government Printing Office, Washington, DC.
7. Henningfield J.E., Goldberg S.R. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol. Biochem. Behav. 19:1983;989-992.
8. Henningfield J.E., Katsumasa M., Jasinski D.R. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled cocaine. J. Pharmacol. Exp. Ther. 24:1985;1-12.
9. Henningfield J.E., Goldberg S.R. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol. Biochem. Behav. 19:1983;1021-1026.
10. Jacob P., Benowitz N.L., Shulgin A.T. Recent studies of nicotine metabolism in humans. Pharmacol. Biochem. Behav. 30:1988;249-253.
11. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12:1971;245-258.
12. Nemeth-Coslett R., Henningfield J.E., O'Keefe M.K., Griffiths R. Effects of mecamylamine on human cigarette consumption. Psychopharmacology (Berlin). 88:1986;420-425.
13. Perkins K.A., Sexton J.A., Reynold W.A., Grobe J.E., Fonte C., Stiller R.L. Comparison of acute subjective and heart rate effects of nicotine intake via tobacco smoking versus nasal spray. Pharmacol. Biochem. Behav. 47:1994;295-299.
14. Pickworth W.B., Herning R.I., Henningfield J.E. Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacol. Biochem. Behav. 30:1988;149-153.
15. Pomerleau C.S., Pomerleau O.F., Majchrzak M.J. Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology (Berlin). 91:1987;391-393.
16. Rose J.E., Sampson A., Levin E.D., Henningfield J.E. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol. Biochem. Behav. 32:1989;933-938.
17. Rose J.E., Levin E.D., Behm F.M., Westman E.C., Stein R.M., Lane J.D., Ripka G.V. Combined administration of agonist-antagonist as a method of regulating receptor activation. Ann. NY Acad. Sci. 757:1995;218-221.
18. Rose J.E., Westman E.C., Behm F.M. Nicotine-mecamylamine treatment for smoking cessation. The role of pre-cessation therapy Exp. Clin. Psychopharmacol. 6:1998;331-343.
19. Rose J.E., Westman E.C., Behm F.M., Johnson M.P., Goldberg J.S. Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol. Biochem. Behav. 62:1999;165-172.
20. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., Ripka G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:1994;86-99.
21. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., Lane J.D., Ripka G.V. Combined effects of nicotine and mecamylamine in attenuating smoking satisfaction. Exp. Clin. Psychopharmacol. 2:1994;328-344.
22. SPSS: SPSS Version 6.1. 1995.
23. Stolerman I.P. Could nicotine antagonists be used in smoking cessation? Br. J. Addict. 81:1986;47-53.
24. Stolerman I.P., Goldfarb T., Fink R., Jarvik M.E. Influencing cigarette smoking with nicotine antagonist. Psychopharmacologia. 28:1973;247-259.
25. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. The pharmacological basis of therapeutics. 9th ed:1996;177-197 McGraw-Hill, New York.